Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

0.6442
-0.0005-0.08%
Volume:232.23K
Turnover:148.21K
Market Cap:12.55M
PE:-0.07
High:0.6548
Open:0.6400
Low:0.6200
Close:0.6447
52wk High:15.75
52wk Low:0.1614
Shares:19.48M
Float Shares:17.03M
Volume Ratio:0.36
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.5973
EPS(LYR):-28.4188
ROE:-1371.64%
ROA:-84.57%
PB:1.08
PE(LYR):-0.02

Loading ...

Moleculin Biotech Highlights Interim Phase 3 AML Data for Annamycin Showing 36% CR, 54% CRc in Pooled Arms

Reuters
·
Yesterday

Moleculin Biotech Updates Investors with New Presentation

TIPRANKS
·
Yesterday

Moleculin Biotech, Inc. : H.c. Wainwright Cuts Target Price to $3 from $22

THOMSON REUTERS
·
Aug 28

U.S. Research Roundup-Dollar General, Palo Alto, Workday

Reuters
·
Aug 28

Moleculin Highlights Interim Data from Pivotal Miracle Phase 2/3 Annamycin Trial in Relapsed/refractory AML

Reuters
·
Aug 27

Moleculin Biotech Announces Annual Shareholder Meeting

Reuters
·
Aug 25

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 17

Traws Pharma Q2 Revenue Falls to Zero on Licensing Termination; Net Loss Widens

Reuters
·
Aug 15

Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate

Benzinga Earnings
·
Aug 14

Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027

Reuters
·
Aug 14

Moleculin Biotech Reports Interim Miracle Trial Data Showing Higher Remission Rates in Relapsed/refractory AML

Reuters
·
Aug 14

Moleculin Biotech Q2 EPS USD -1.4

THOMSON REUTERS
·
Aug 14

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal Miracle Trial

THOMSON REUTERS
·
Aug 14

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

GlobeNewswire
·
Aug 14

Moleculin Biotech Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Moleculin Net Loss Narrows to $7.64 Million in Q2 FY26; R&D Expense Rises to $5.45 Million

Reuters
·
Aug 14

Moleculin Biotech Inc Expected to Post a Loss of $1.54 a Share - Earnings Preview

Reuters
·
Aug 08

Moleculin Biotech Chief Science Officer Donald H. Picker Acquires Common Shares Worth $129,999.75

Reuters
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (MBRX), Merit Medical Systems (MMSI) and Moderna (MRNA)

TIPRANKS
·
Aug 01

NASDAQ Trade Halt Volatility Trading Pause at 10:12 Am

Reuters
·
Jul 31